Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Biotech
Exicure buys GPCR's US unit and clinical-stage blood cancer drug
The deal will see Exicure take control of the CXCR4 antagonist burixafor, which is being assessed in a phase 2 trial of patients with blood cancer.
James Waldron
Jan 23, 2025 5:01am
Incyte scraps cancer-related anemia program after ph. 1/2 fail
Dec 13, 2024 2:30pm
Lava burnt by failure clinical-stage cancer drug in phase 1
Dec 10, 2024 9:15am
AbbVie sues BeiGene over blood cancer drug trade secrets
Sep 11, 2024 10:17am
FDA rejects Regeneron bispecific, delaying rival to J&J, Pfizer
Aug 21, 2024 5:48am
FDA hands de novo clearance to Scopio's bone marrow pathology AI
Apr 17, 2024 12:56pm
